{"disease":{"id":"advanced-lung-cancer","name":"advanced lung cancer"},"drugs":{"marketed":[{"drug_id":"amivantamab","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rybrevant","generic_name":"AMIVANTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"EGFR, MET","drug_class":"","quality_score":59,"revenue":"800","mechanism":"Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells."},{"drug_id":"selpercatinib","indication_name":"Advanced RET fusion-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"sotorasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumakras","generic_name":"SOTORASIB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":65,"revenue":"300","mechanism":"Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth."},{"drug_id":"adagrasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Krazati","generic_name":"ADAGRASIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":66,"revenue":"205","mechanism":"Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth."},{"drug_id":"repotrectinib","indication_name":"Locally advanced or metastatic ROS1-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augtyro","generic_name":"REPOTRECTINIB","company_name":"Bristol","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":"200","mechanism":"Augtyro blocks the activity of ROS1 and NTRK kinases, which are abnormal proteins that help cancer cells grow and spread."},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with an activating EGFR mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with a tumor harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."},{"drug_id":"amivantamab-vmjw","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RYBREVANT","generic_name":"AMIVANTAMAB-VMJW","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor, Hepatocyte growth factor receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"taletrectinib","indication_name":"locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibtrozi","generic_name":"TALETRECTINIB","company_name":"Nuvation","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Ibtrozi works by blocking the ROS1 protein, which is a genetic mutation found in some lung cancer cells."},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"brigatinib","indication_name":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alunbrig","generic_name":"brigatinib","company_name":"Takeda","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells."},{"drug_id":"ensartinib","indication_name":"ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ensacove","generic_name":"ENSARTINIB","company_name":"Xcovery","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Ensartinib works by inhibiting a specific protein that drives the growth of cancer cells."},{"drug_id":"deruxtecan","indication_name":"Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Datroway","generic_name":"DERUXTECAN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Deruxtecan works by binding to and inhibiting the growth of cancer cells."},{"drug_id":"mobocertinib","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exkivity","generic_name":"MOBOCERTINIB","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-4","drug_class":"Kinase Inhibitor","quality_score":28,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"pf-06439535-cn","indication_name":"Advanced non-squamous non-small-cell lung cancer (NSCLC)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06439535 (CN)","generic_name":"pf-06439535-cn","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design","drug_class":"Selective pathway inhibitor; presumed anti-angiogenic agent","quality_score":null,"revenue":null,"mechanism":"Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells."},{"drug_id":"pf-07820435","indication_name":"Advanced solid tumors (non-small-cell lung cancer, melanoma)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07820435","generic_name":"pf-07820435","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications","drug_class":"Protease inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival."}],"offLabel":[],"totalMarketed":15,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT06613633","title":"Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC","phase":"","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05339568","title":"Patient's Whole Process Follow-up Management(HOPE-1)","phase":"","overall_status":"RECRUITING","enrollment_count":1268,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT06269133","title":"Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07164885","title":"RAPART in Locally Advanced Non-small Cell Lung Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":911,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT07309276","title":"A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":864,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05785767","title":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":850,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07485166","title":"Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":810,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04613596","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":806,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":false},{"nct_id":"NCT06604689","title":"AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06073431","title":"LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT07485179","title":"Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":770,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06963502","title":"A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":762,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT02296125","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":674,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07459751","title":"A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":671,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT02658890","title":"An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":627,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT05673590","title":"Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":612,"lead_sponsor_name":"Beijing Biostar Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT01526928","title":"Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":612,"lead_sponsor_name":"Clovis Oncology, Inc.","has_results":true},{"nct_id":"NCT04416035","title":"A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":608,"lead_sponsor_name":"Zhejiang Teruisi Pharmaceutical Inc.","has_results":false},{"nct_id":"NCT01802632","title":"AZD9291 First Time In Patients Ascending Dose Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":603,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06418412","title":"A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT05450692","title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":594,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05132413","title":"A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":561,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03117335","title":"Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05840016","title":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":532,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT01933932","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":510,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT01980212","title":"Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT07150598","title":"Immune-Marker Platform for Patients With Advanced Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT06075524","title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07288632","title":"Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University Of Perugia","has_results":false},{"nct_id":"NCT06734702","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT07524257","title":"ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":494,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT05624996","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":474,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06644430","title":"Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03856411","title":"A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":465,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05048797","title":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":454,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04685135","title":"Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":453,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":true},{"nct_id":"NCT06452277","title":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":444,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06881784","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06791057","title":"Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":420,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06980272","title":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Shenyang Sunshine Pharmaceutical Co., LTD.","has_results":false},{"nct_id":"NCT05388669","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":418,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT07169994","title":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":414,"lead_sponsor_name":"MediLink Therapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT03948724","title":"Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology","phase":"NA","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"Institut Cancerologie de l'Ouest","has_results":false},{"nct_id":"NCT07259226","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"UNICANCER","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}